STL Index for: TCS

Real World Canadian Case Series: Use of Tildrakizumab for Moderate-to-Severe Psoriasis

Psoriasis vulgaris, or plaque psoriasis, is a chronic systemic inflammatory disease characterized by scaly, erythematous plaques. It is associated with comorbidities such as cardiovascular disease, metabolic syndrome, depression, and anxiety, signifi cantly aff ecting patients' quality of life. Tildrakizumab, an IL-23 inhibitor, is approved for treating adults with moderate-to-severe plaque psoriasis.

Lebrikizumab for Moderate-to-Severe Atopic Dermatitis

Lebrikizumab is a new IL-13 targeting monoclonal antibody approved for moderate-to-severe atopic dermatitis in patients 12+ years. Learn about clinical trial efficacy, safety data, dosing, and how it compares to other AD biologics like dupilumab and tralokinumab.

Nanodermatology

Nanodermatology uses nanoparticles (1-1000 nanometers) to enhance transdermal drug delivery for treating psoriasis, vitiligo, acne, and atopic dermatitis. Learn about nanocarriers, liposomes, and how nanotechnology improves topical medication penetration while reducing side effects.

A Multimodal Approach to Acne-Induced Post-Inflammatory Hyperpigmentation: Trifarotene as a Long-Term Intervention

Discover how trifarotene, a fourth-generation retinoid, effectively treats acne and post-inflammatory hyperpigmentation (PIH). Learn about its benefits, clinical evidence, and role in managing acne sequelae.

Real-World Insights from Atopic Dermatitis Patients Treated with Abrocitinib

This real-world case series intends to illustrate a variety of moderate-to-severe AD patient cases to help guide discussions around abrocitinib and describe its treatment strategies used by experts in the field.

Dupilumab for the Treatment of Prurigo Nodularis

Dupilumab: A groundbreaking FDA and Health Canada-approved treatment for Prurigo Nodularis (PN). This innovative therapy targets IL-4 and IL-13 signalling, effectively reducing inflammation, pruritus, and lesions. Its approval marks a paradigm shift in PN management, offering new hope for patients.

A Practical Guide to Advanced Topical Drug Delivery Systems in Dermatology

This guide will help you navigate the benefits of recent advancements in topical drug formulations and delivery systems. These innovations address limitations seen in older formulations, ensuring efficient and uniform delivery of active ingredients to target areas, improving patient acceptability, and enhancing treatment outcomes.

Managing Psoriasis with Topical Agents – Where Do We Stand?

Psoriasis vulgaris is a chronic, immune-mediated inflammatory skin disease affecting 2-4% of the Canadian population. While most psoriasis vulgaris cases are mild-to-moderate (>80%) and do not require systemic treatment, these cases can still be particularly challenging to treat as topical therapies present limitations, including efficacy and administration, leading to poor long-term treatment compliance and unsatisfactory treatment responses. The intent of this paper is to provide physicians with a clinically relevant review of the currently available and newly developed topical therapies...

Tralokinumab for Moderate-to-Severe Atopic Dermatitis in Adults

Tralokinumab is an effective and safe treatment for adult patients with moderate-to-severe AD. It may be used alone or in combination with TCS. This biologic can be considered first-line treatment after failure of or intolerance to topical therapies.

Casmo Algorithm for Management of Hormonal Therapy-Related Cutaneous Adverse Effects in Oncology Patients

Breast and prostate cancer patients frequently use hormonal therapy to improve treatment outcomes and survival. However, these medications can be associated with numerous dermatologic adverse effects.

CaSMO Management of Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: A Practical Primer

The management of cirAEs starts with physician awareness and patient education on the occurrence of toxicities, preventive measures, and skincare using gentle cleansers, moisturizers, and sunscreen started before immunotherapy begins and ongoing thereafter as part of the lifestyle.

Update on Drugs & Devices: July-August 2022

Update covering: Benzoyl peroxide 5% cream, Isotretinoin ointment, Tapinarof 1% cream, Baricitinib tablets, and Dupilumab for SC injection.

Halobetasol Propionate 0.01% Lotion for Plaque Psoriasis and Corticosteroid-Responsive Dermatoses

A novel topical corticosteroid, halobetasol propionate (HP) 0.01% lotion (Bryhali™), has recently been introduced for the treatment of plaque psoriasis and corticosteroid-responsive dermatoses in adults.

Janus Kinase and Tyrosine Kinase Inhibitors in Dermatology: A Review of Their Utilization, Safety Profile and Future Applications

Currently, JAK inhibitors are only FDA approved for dermatologic, rheumatologic, and hematologic conditions. Recent studies show the utility of JAK inhibitors in treating atopic dermatitis, psoriasis, psoriatic arthritis, vitiligo, and alopecia areata.

How to Use Halobetasol Propionate and Tazarotene Lotion to Treat Psoriasis

A fixed combination halobetasol propionate and tazarotene lotion (HP/TAZ) was launched in Canada in 2020, to treat moderate to severe plaque psoriasis in adults. With the use of polymeric emulsion technology, there is uniform distribution of HP and TAZ and excipients on the skin and improved skin moisturization.

Canadian Skin Management in Oncology Group (Casmo) Algorithm for the Prevention and Management of Acute Radiation Dermatitis

The Canadian Skin Management in Oncology Group (CaSMO) developed an algorithm for the reduction of severity and management of acute RD, which follows previous publications from this group that addressed general oncology-treatment related cutaneous adverse events [AEs], prevention, and skin management.

Optimal Use of Crisaborole in Atopic Dermatitis – An Expert Guidance Document

Mild to moderate atopic dermatitis (AD) is often controlled by behavioral measures such as skincare and avoidance of triggers in addition to topical treatments such as topical corticosteroids (TCS), topical calcineurin inhibitors (TCI), and crisaborole, a phosphodiesterase-4 inhibitor (PDE4-I).

Crisaborole 2% Ointment for Mild-to-Moderate Atopic Dermatitis

Crisaborole provides a novel and safe treatment option for mild-to-moderate AD.

Use of Topical Crisaborole for Treating Dermatitis in a Variety of Dermatology Settings

The discussed cases reflect the panels’ real-world clinical experience with crisaborole for the treatment of patients with AD and the off-label treatment of irritant dermatitis.

Diagnosis and Management of Atopic Dermatitis for Family Physicians: A Clinical Review

Atopic dermatitis (AD) is a chronic and pruritic inflammatory disease that affects a wide age range of patients causing significant impact on their quality of life. There has been a recently updated consensus paper on the treatment of mild-to-moderate AD published by an expert panel of dermatologists and pediatricians. Family physicians are well equipped to manage...

Update on the Management of Vitiligo

Vitiligo is a psychosocially debilitating disease requiring a multidisciplinary approach to treatment. Patients should be made aware of all of the options available geared at repigmentation and depigmentation prior to formulating a treatment plan.

Crisaborole 2% Ointment (Eucrisa) for Atopic Dermatitis

Crisaborole represents a novel and efficacious therapeutic approach for the treatment of mild to moderate Atopic Dermatitis and demonstrates early and continued decrease in pruritus, which improves quality of life and reduces the potential risk of infection and scarring.

Atopic Dermatitis: Pediatric Use of Crisaborole

An overview to AD care and focus our review to topical agents used in AD including topical corticosteroids (TCS) and topical calcineurin inhibitors (TCI) and discuss the newest topical agent accessible in the physician's armamentarium, crisaborole.

Atopic Dermatitis: A Practical Guide to Management

A group of dermatologists with extensive experience in managing pediatric and adult patients with atopic dermatitis developed practical recommendations for the management of atopic dermatitis based on expert consensus opinion and the best available medical evidence.

Chronic Hand Dermatitis: Case-based Approaches to Management

Practical guidelines for the management of Chronic Hand Dermatitis were published in the Skin Therapy Letter, Family Practice Edition (October 2016). This series of cases using Alitretinoin (Toctino®), is a follow on to that publication to put the guidelines into context.

Management of Adult Moderate-to-Severe Atopic Dermatitis: A Practical Guide for Primary Care

Atopic dermatitis (AD) is a chronic, relapsing, pruritic, inflammatory condition involving the skin which can have a significant impact on the quality of life. This article will guide the family practitioner on how to manage adults with moderate-to-severe AD and when to refer for specialist management.

Management of Chronic Hand Dermatitis: A Practical Guideline for the General Practitioner

Hand Dermatitis can have a significant impact on quality of life. It may interfere with activities both at work and in the home and can be associated with social and psychological distress. This article provides helpful practical guidance for the general practitioner in the management of patients with Hand Dermatitis.

Off-Label Uses of Topical Calcineurin Inhibitors

Topical calcineurin inhibitors (TCIs) have been proposed as an alternative, long-term treatment option to topical corticosteroids. Currently, TCIs are only approved for treatment of atopic dermatitis in patients 2 years of age or older. This article reviews the off-label uses of TCIs and their efficacy in the treatment of cutaneous diseases.

Current Management of Scalp Psoriasis

The scalp is involved in up to 80% of individuals with psoriasis. Topical treatment with corticosteroids with or without vitamin D3 analogues is the mainstay of treatment, but other therapies such as light treatment and systemic drugs including biologics are discussed.

Pregnancy-Specific Skin Disorders

This articles discusses pregnancy-specific skin disorders: Pemphigoid gestationis, polymorphic eruption of pregnancy, atopic eruption of pregnancy, and intrahepatic cholestasis of pregnancy. Clinical presentation, potential for fetal complications, pathogenesis, diagnosis, and treatment are discussed.

Steroid-Sparing Properties of Emollients in Dermatology

This article reviews topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs) to manage inflammatory conditions, its risks with long-term use, and the role of moisturizing as important therapeutic adjuncts.

Therapeutic Options for Vitiligo

Vitiligo is a disease that presents with depigmented skin and is associated with significant psychosocial effects. Disease progression can be unpredictable and management is challenging. This article discusses etiology, management, and treatment options.

A New Paradigm Shift in the Management of Atopic Dermatitis (Pediatric Edition)

This article reviews atopic dermatitis, and its shift in the philosophy behind treatment and management. Preventative therapy, long-term strategy, and focus on quality of life.

A New Paradigm Shift in the Management of Atopic Dermatitis

Atopic eczema (or atopic dermatitis) is a common inflammatory skin condition that dermatologists, pediatricians, family physicians, and primary-care providers see on a daily basis. Treatments, mechanism of action, preventative therapies, and the skin barrier are discussed.

Topical Management of Recalcitrant Psoriasis and Eczema

Psoriasis and eczema, especially atopic eczema, are two of the most common cutaneous conditions seen by family physicians and dermatologists. This article discusses the etiology of psoriasis and eczema, immunologic abnormalities, and the role of immune mediators.

A New Paradigm Shift in the Management of Atopic Dermatitis (Pharmacist Edition)

Atopic eczema is a chronic condition and a long view is necessary for disease control and management. This article discusses the important role of the skin barrier and how it may be a target for therapeutics in treating atopic eczema.

Propylene Glycol: An Often Unrecognized Cause of Allergic Contact Dermatitis in Patients Using Topical Corticosteroids

Propylene glycol (PG) is considered to be a ubiquitous formulary ingredient used in many personal care products and pharmaceutical preparations. This review guides clinicians in selecting suitable topical corticosteroids.

Overview of Treatment of Vulvovaginal Disease

Vulvovaginal diseases commonly are inadequately diagnosed and treated. This article discusses the important role dermatologists play in identifying irregular presentations, recognizing skin problems, and addressing itch, pain, and inflammation.

Therapeutic Moisturizers in Eczema and Xerosis Management

Psoriasis and eczema, especially atopic eczema, are two of the most common cutaneous conditions seen by family physicians and dermatologists. This article focuses on corticosteroids of varying strengths and their suggested indications.

Current Effective Topical Therapies in the Management of Psoriasis

Topical therapy forms the cornerstone of treatment in the management of psoriasis. Topical options, vehicle advances, and treatment efficacy of several topicals are discussed for managing psoriasis.

POPULAR

Advertisement